4.6 Article

Chronic kidney disease

期刊

NATURE REVIEWS DISEASE PRIMERS
卷 3, 期 -, 页码 -

出版社

NATURE PORTFOLIO
DOI: 10.1038/nrdp.2017.88

关键词

-

资金

  1. European Research Council under the Consolidator Grant RENOIR [648274]
  2. European Union's research and innovation programme [634086]
  3. French government (the Investisssement d'Avenir programme)
  4. Deutsche Forschungsgemeinschaft [AN372/16-2, AN372/23-1, AN372/24-1]
  5. H2020 Societal Challenges Programme [634086] Funding Source: H2020 Societal Challenges Programme

向作者/读者索取更多资源

Chronic kidney disease (CKD) is defined by persistent urine abnormalities, structural abnormalities or impaired excretory renal function suggestive of a loss of functional nephrons. The majority of patients with CKD are at risk of accelerated cardiovascular disease and death. For those who progress to end-stage renal disease, the limited accessibility to renal replacement therapy is a problem in many parts of the world. Risk factors for the development and progression of CKD include low nephron number at birth, nephron loss due to increasing age and acute or chronic kidney injuries caused by toxic exposures or diseases (for example, obesity and type 2 diabetes mellitus). The management of patients with CKD is focused on early detection or prevention, treatment of the underlying cause (if possible) to curb progression and attention to secondary processes that contribute to ongoing nephron loss. Blood pressure control, inhibition of the renin-angiotensin system and disease-specific interventions are the cornerstones of therapy. CKD complications such as anaemia, metabolic acidosis and secondary hyperparathyroidism affect cardiovascular health and quality of life, and require diagnosis and treatment.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Transplantation

Intravenous Glu-plasminogen attenuates cholesterol crystal embolism-induced thrombotic angiopathy, acute kidney injury and kidney infarction

Lyuben Lyubenov, Chongxu Shi, Danyang Zhao, Luying Yang, Yutian Lei, Elmina Mammadova-Bach, Letizia de Chiara, Roberto Semeraro, Samuela Landini, Paola Romagnani, Elena Voerg, Satish K. Devarapu, Ricarda Welz, Stephan T. Kiessig, Hans-Joachim Anders

Summary: Cholesterol crystal (CC) embolism leads to acute kidney injury (AKI) and ischaemic cortical necrosis with high mortality. Injection of Glu-plasminogen (Glu-Plg) showed a dose-dependent attenuation of thrombotic angiopathy, GFR loss, and ischaemic necrosis in mice with CC embolism. Intermediate dose of Glu-Plg had transient protective effect, while high dose provided full protection without bleeding complications.

NEPHROLOGY DIALYSIS TRANSPLANTATION (2023)

Article Medicine, General & Internal

Diabetes Management in Chronic Kidney Disease: Synopsis of the KDIGO 2022 Clinical Practice Guideline Update

Sankar D. Navaneethan, Sophia Zoungas, M. Luiza Caramori, Juliana C. N. Chan, Hiddo J. L. Heerspink, Clint Hurst, Adrian Liew, Erin D. Michos, Wasiu A. Olowu, Tami Sadusky, Nikhil Tandon, Katherine R. Tuttle, Christoph Wanner, Katy G. Wilkens, Jonathan C. Craig, David J. Tunnicliffe, Marcello Tonelli, Michael Cheung, Amy Earley, Peter Rossing, Ian H. de Boer, Kamlesh Khunti

Summary: The KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease is an update of the 2020 guideline. The guideline was updated based on reviewing new evidence and using the GRADE approach to assess evidence and develop consensus practice points. The recommendations were updated in the areas of comprehensive care and glucose-lowering therapies, while recommendations in the areas of glycemic monitoring, lifestyle interventions, and management approaches remained unchanged.

ANNALS OF INTERNAL MEDICINE (2023)

Review Immunology

Immunological reviews: The alternative pathway or amplification loop of complement

Erica Daina, Monica Cortinovis, Giuseppe Remuzzi

Summary: Dysregulation and accelerated activation of the alternative pathway of complement play important roles in kidney diseases, and complement-directed therapies have shown potential for treatment. Although there have been successful cases, incorporating these therapies into clinical practice still faces challenges.

IMMUNOLOGICAL REVIEWS (2023)

Article Cardiac & Cardiovascular Systems

Self-Management Support Using Advertising Principles for Older Adults With Low Income at High Cardiovascular Risk: A Randomized Controlled Trial

David J. T. Campbell, Marcello R. Tonelli, Brenda Hemmelgarn, Peter Faris, Jianguo Zhang, Flora T. Au, Ross Tsuyuki, Chad Mitchell, Raj Pannu, Tavis Campbell, Noah Ivers, Jane V. Fletcher, Derek J. Exner, Braden Manns

Summary: In a randomized trial conducted in Alberta, Canada, a tailored self-management education and support (SMES) program designed using advertising principles was found to reduce the rate of clinical outcomes among low-income older adults. The intervention included health promotion messaging and relay of clinical information to patients' healthcare providers. The study showed that the rate of the primary outcome, including death, myocardial infarction, stroke, coronary revascularization, and hospitalizations for cardiovascular-related conditions, was lower in the SMES group compared to the control group.

CIRCULATION (2023)

Review Biochemistry & Molecular Biology

Role of Sex Hormones in Prevalent Kidney Diseases

Carolina Conte, Giulia Antonelli, Maria Elena Melica, Mirko Tarocchi, Paola Romagnani, Anna Julie Peired

Summary: Chronic kidney disease (CKD) is a global health burden affecting over 840 million people worldwide. It presents sex disparities in its pathophysiology, epidemiology, clinical manifestations, and disease progression. While CKD is more frequent in females, males have a higher risk of progressing to end-stage kidney disease. Recent studies have highlighted the role of sex hormones in the development and progression of CKD.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Article Public, Environmental & Occupational Health

Lessons learned from implementing the Non-Communicable Diseases Kit in a humanitarian emergency: an operational evaluation in Sudan

Ahmad Hecham Alani, Laura Miller, Isaac Waweru, Aston B. Atwiine, Stella Njagi, Marcello Tonelli, Kelly Kisarach, Abdelrhman Mohammed, Ronald Mugera, Nazik Mohamed Ibrahim, Dina Abdulhammed Mohamad, Lilian Kiapi

Summary: Non-communicable diseases (NCDs) pose a significant global health challenge, especially in humanitarian contexts with limited healthcare resources. The WHO Non-Communicable Diseases Kit (WHO-NCDK) is an intervention aimed at primary healthcare facilities in emergency situations, providing essential medicines and equipment for NCD management. An operational evaluation in Sudan found that the kit played a critical role in ensuring continuity of care during disruptions in the supply chain. However, contextual factors such as community familiarity with healthcare facilities, integration of NCDs into primary healthcare, and monitoring and evaluation systems were identified as important considerations for enhancing the kit's utility.

BMJ GLOBAL HEALTH (2023)

Article Endocrinology & Metabolism

MAFLD and glomerular hyperfiltration in subjects with prediabetes, visceral obesity and preserved kidney function: A cross-sectional study

Aneliya Parvanova, Manuela Abbate, Aina Maria Yanez, Miquel Bennasar-Veny, Angel Arturo Lopez-Gonzalez, Jose Ignacio Ramirez-Manent, Ilian Petrov Iliev, Sergio Fresneda, Maria Arias-Fernandez, Giuseppe Remuzzi, Piero Ruggenenti

Summary: This study investigated the prevalence of metabolic dysfunction-associated fatty liver disease (MAFLD) in prediabetes, visceral obesity, and preserved kidney function, and explored the association between MAFLD and hyperfiltration. It was found that MAFLD was more frequent in hyperfiltering subjects and was independently associated with hyperfiltration, as well as potentiated the age-related decline in estimated glomerular filtration rate (eGFR).

DIABETES RESEARCH AND CLINICAL PRACTICE (2023)

Article Biochemistry & Molecular Biology

Hypoimmunogenic Human Pluripotent Stem Cells as a Powerful Tool for Liver Regenerative Medicine

Piera Trionfini, Elena Romano, Marco Varinelli, Lorena Longaretti, Paola Rizzo, Roberta Giampietro, Annalina Caroli, Sistiana Aiello, Marta Todeschini, Federica Casiraghi, Giuseppe Remuzzi, Ariela Benigni, Susanna Tomasoni

Summary: Induced pluripotent stem cells (iPSC) have the potential for cell therapy due to their self-renewal and differentiation capabilities. However, the high production costs and limited use for acute conditions hinder their applications. An allogeneic iPSC-based strategy may overcome these issues, but immune rejection is a concern. In this study, CRISPR/Cas9 was used to create hypoimmunogenic iPSCs that can differentiate into liver cells, providing a cost-effective and off-the-shelf opportunity for liver disease cell therapy.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Article Urology & Nephrology

Safety and Preliminary Efficacy of Mesenchymal Stromal Cell (ORBCEL-M) Therapy in Diabetic Kidney Disease: A Randomized Clinical Trial (NEPHSTROM)

Norberto Perico, Giuseppe Remuzzi, Matthew D. Griffin, Paul Cockwell, Alexander P. Maxwell, Federica Casiraghi, Nadia Rubis, Tobia Peracchi, Alessandro Villa, Marta Todeschini, Fabiola Carrara, Bernadette A. Magee, Piero L. Ruggenenti, Stefano Rota, Laura Cappelletti, Veronica Mcinerney, Tomas P. Griffin, Md Nahidul Islam, Martino Introna, Olga Pedrini, Josee Golay, Andrew A. Finnerty, Jon Smythe, Willem E. Fibbe, Stephen J. Elliman, Timothy O'Brien, NEPHSTROM Trial Consortium

Summary: The NEPHSTROM study evaluates the safety, tolerability, and preliminary efficacy of ORBCEL-M cell therapy in adults with type 2 diabetes and progressive diabetic kidney disease. The results show that ORBCEL-M cell therapy is safe and well-tolerated in the lowest dose cohort, and significantly reduces the decline rate of eGFR over 18 months.

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2023)

Article Urology & Nephrology

Finerenone Added to RAS/SGLT2 Blockade for CKD in Alport Syndrome. Results of a Randomized Controlled Trial with Col4a3(-/-) Mice

Zhihui Zhu, Karoline A. T. Rosenkranz, Yoshihiro Kusunoki, Chenyu Li, Martin Klaus, Oliver Gross, Maria-Lucia Angelotti, Giulia Antonelli, Luigi Cirillo, Paola Romagnani, Nassim Bouteldja, Alireza Vafaei Sadr, Roman D. Buelow, Peter Boor, Hans-Joachim Anders

Summary: A preclinical study in mice suggests that triple blockade of RAS/SGLT2/MR may significantly improve renal outcomes in Alport syndrome and other progressive CKDs due to synergistic effects on the glomerular and tubulointerstitial compartments.

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2023)

Review Urology & Nephrology

Measuring albuminuria or proteinuria: does one answer fit all?

Tyrone G. Harrison, Marcello Tonelli

Summary: The measurement of proteinuria is crucial for diagnosing and monitoring kidney disease, but there is still controversy and uncertainty surrounding the optimal measurement method. International guidelines recommend the use of urinary albumin-to-creatinine ratio, but this method is not universally available and can be costly. Additionally, the accuracy of different measurement methods may vary depending on the magnitude of albuminuria, sex, and clinical contexts.

KIDNEY INTERNATIONAL (2023)

Review Urology & Nephrology

Disasters and kidney care: pitfalls and solutions

Mehmet Sukru Sever, Valerie Luyckx, Marcello Tonelli, Rumeyza Kazancioglu, Darlene Rodgers, Dani Gallego, Serhan Tuglular, Raymond Vanholder

Summary: Patients with kidney disease are more vulnerable to the adverse effects of disasters due to their reliance on infrastructure, technology, drugs, and medical personnel. Pre-disaster preparedness, training, and emergency responses can help mitigate risks and improve outcomes for these patients.

NATURE REVIEWS NEPHROLOGY (2023)

Article Medicine, General & Internal

Rationale and design of the CV-PREVITAL study: an Italian multiple cohort randomised controlled trial investigating innovative digital strategies in primary cardiovascular prevention

Damiano Baldassarre, Licia Iacoviello, Roberta Baetta, Maria Carla Roncaglioni, Gianluigi Condorelli, Giuseppe Remuzzi, Gianfranco Gensini, Luigi Frati, Walter Ricciardi, Pier Giulio Conaldi, Antonio Uccelli, Fabio Blandini, Silvano Bosari, Giovanni Scambia, Massimo Fini, Antonio Di Malta, Mauro Amato, Fabrizio Veglia, Alice Bonomi, Catherine Klersy, Francesca Colazzo, Martino Pengo, Francesca Gorini, Luciana Auteri, Giuseppe Ferrante, Marta Baviera, Giuseppe Ambrosio, Alberico Catapano, Alessandro Gialluisi, Alexis Elias Malavazos, Serenella Castelvecchio, Massimiliano Marco Corsi-Romanelli, Rosanna Cardani, Maria Teresa La Rovere, Valentina Agnese, Bianca Pane, Daniele Prati, Laura Spinardi, Giovanna Liuzzo, Eloisa Arbustini, Maurizio Volterrani, Marco Visconti, Jose Pablo Werba, Stefano Genovese, Grzegorz Bilo, Cecilia Invitti, Anna Di Blasio, Carolina Lombardi, Andrea Faini, Debora Rosa, Luisa Ojeda-Fernandez, Andreana Foresta, Amalia De Curtis, Augusto Di Castelnuovo, Simonetta Scalvini, Antonia Pierobon, Alessandra Gorini, Luca Valenti, Livio Luzi, Annarosa Racca, Manuela Bandi, Elena Tremoli, Lorenzo Menicanti, Gianfranco Parati, Giulio Pompilio

Summary: The CV-PREVITAL study is a multicentre, prospective, randomised, controlled, open-label interventional trial aiming to compare the effectiveness of an educational and motivational mobile health intervention with usual care in reducing cardiovascular risk. The trial plans to enrol approximately 80,000 subjects without overt cardiovascular diseases and evaluate the short-term endpoints, as well as conduct a long-term follow-up to assess the incidence of major adverse cardiovascular events.

BMJ OPEN (2023)

Review Urology & Nephrology

The long-term benefits of early intensive therapy in chronic diseases-the legacy effect

Carmine Zoccali, Francesca Mallamaci, Giovanni Tripepi, Edouard L. Fu, Vianda S. Stel, Friedo W. Dekker, Kitty J. Jager

Summary: The 'legacy effect' describes the long-term benefits of intensive therapy in reducing complications and mortality in chronic diseases. It is evident in studies related to chronic kidney disease (CKD) and highlights the importance of intensive treatment. However, the legacy effect is more pronounced in early-stage diabetes and less evident in long-term, established diabetes patients.

CLINICAL KIDNEY JOURNAL (2023)

Article Biochemistry & Molecular Biology

Endothelial Glycocalyx of Peritubular Capillaries in Experimental Diabetic Nephropathy: A Target of ACE Inhibitor-Induced Kidney Microvascular Protection

Monica Locatelli, Daniela Rottoli, Rayan Mahmoud, Mauro Abbate, Daniela Corna, Domenico Cerullo, Susanna Tomasoni, Giuseppe Remuzzi, Carlamaria Zoja, Ariela Benigni, Daniela Macconi

Summary: In BTBR ob/ob mice with type 2 diabetic nephropathy, peritubular capillaries show endothelial cell abnormalities and basement membrane thickening. Remodeling and focal loss of the endothelial glycocalyx were observed in diabetic kidneys, and ACEi treatment preserved the glycocalyx and attenuated the ultrastructural abnormalities of peritubular capillaries.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

暂无数据